Burkehill Global Management’s Apogee Therapeutics APGE Stock Holding History

Burkehill Global Management’s Portfolio APGE Stock Details APGE Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	$2.53M	Buy	+30,000	New	+$2.18M	0.13%	113

Other funds holding APGE

T. Rowe Price Investment Management Baltimore, Maryland $145B AUM 22.78% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

VR Adviser New York $2.68B AUM 422.73% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

RTW Investments New York $10B AUM 135.35% 1-Year Est. Return

VCM

Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

DCM

Driehaus Capital Management Chicago, Illinois $13.6B AUM 173.98% 1-Year Est. Return

Burkehill Global Management's APGE Position: Q1 2026 in Review

Burkehill Global Management opened a new position in Apogee Therapeutics (APGE) in Q1 2026: 30,000 shares worth $2.53M. The stake represents 0.13% of the portfolio and ranks #113 among its holdings.

224 funds tracked by Wall St. Rank hold APGE as of Q1 2026.

Burkehill Global Management held 30,000 shares of Apogee Therapeutics worth $2.53M as of Q1 2026.
Apogee Therapeutics was a new Burkehill Global Management position in Q1 2026.
Apogee Therapeutics made up 0.13% of Burkehill Global Management's portfolio in Q1 2026, its #113 holding.
224 funds tracked by Wall St. Rank held Apogee Therapeutics as of Q1 2026.

Based on Burkehill Global Management's 13F filing for Q1 2026, filed 15 May 2026.